A legal right to obtain marketed cancer drugs at cost for combination trials
If a company refuses to supply its approved drug for a well-designed independent trial combining it with a rival's drug, the law would let the trial buy it at manufacturing cost, with results shared back.
A research-access provision, analogous to compulsory licensing but for trial supply: an independent scientific committee can certify an academic or non-profit combination trial as in the public interest, after which the patent holder must supply the drug at a regulated cost-of-goods price or license a generic maker to do so, in exchange for full access to the trial's data and a right to use results in labelling. The provision only bites when voluntary agreement fails and so mostly changes bargaining positions. It addresses the documented pattern of companies declining to supply comparators or partners for trials that might disadvantage their product.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
Pages like this
not linked directly; found by shared links- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaUniversity licences with royalties indexed to benefit and global access
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaA patent pool for combination method-of-use claims
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaEvery approved cancer drug ships with a public combination-readiness data pack
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA single oncology trial data trust with mandatory deposit within eighteen months
Shares An antitrust safe harbour for cross-company combination trials and data pooling, Secrecy and intellectual property block collaboration.
- IdeaA standard cross-company combination agreement that takes weeks, not years, to sign
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA publicly held library of investigational drugs available for academic combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.